---
title: "Obefazimod (ABX464) in Ulcerative colitis: Long-term morbidity"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Long-term morbidity. Topics: Colectomy: 10% to 20% of patients require proctocolectomy for refractory disease; Colorectal cancer: risk by disease duration and extent; Colorectal cancer: Danish and Swedish cohort of 96,447 patients, 1969 to 2017; Extraintestinal manifestations: joint, ocular, or skin manifestations in 27% of patients; 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Colectomy: 10% to 20% of patients require proctocolectomy for refractory disease

> “Although the therapeutic options are expanding, 10-20% of patients still require proctocolectomy for medically refractory disease.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “The 5- and 10-year cumulative risk of colectomy is 10–15%; achieving mucosal healing is associated with lower risk of colectomy.”
> “Disease extent consistently influences risk of colectomy (OR 2.2; 95% CI, 1.1–4.3), with significantly higher risk in patients with extensive colitis (10y cumulative risk, 19%), followed by left-sided colitis (8%) and ulcerative proctitis (5%) (16,18,20).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “Indications for colectomy in UC include (i) ASUC or (ii) chronic refractory UC not responding to traditional medical therapy or (iii) development of dysplasia and/or carcinoma in chronic UC.”
> “Extensive colitis, deep ulcers by endoscopy, need for systemic steroids, young age at diagnosis (younger than 30 years), and elevated CRP or ESR are associated with higher rates of colectomy (96,98).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.7-2"></a>

### Colorectal cancer: risk by disease duration and extent

> “The risk of colorectal cancer after 20 years of disease duration is 4.5%, and people with UC have a 1.7-fold higher risk for colorectal cancer compared with the general population.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “Cumulative probability of CRC at 10, 20, and 30 years after UC diagnosis was 0.4–0.6%, 1.1–5.4%, and 2.1–7.5%, respectively (43,44). This risk is increased in patients with pancolitis (SIR, 2.4–14.8) and left-sided colitis (SIR, 1.4–2.8), but not in patients with proctitis (41,45–47). Young age at diagnosis, male sex, extensive colitis, disease duration and concomitant primary sclerosing cholangitis have been consistently identified as risk factors of CRC.”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “Longstanding UC is also associated with a defined risk of dysplasia and colorectal cancer (CRC) which is believed to be primarily related to more extensive bowel involvement and longstanding mucosal inflammatory activity (9–11).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.7-3"></a>

### Colorectal cancer: Danish and Swedish cohort of 96,447 patients, 1969 to 2017

> “During follow-up, we observed 1336 incident CRCs in the UC cohort (1·29 per 1000 person-years) and 9544 incident CRCs in reference individuals (0·82 per 1000 person-years; HR 1·66, 95% CI 1·57-1·76). In the UC cohort, 639 patients died from CRC (0·55 per 1000 person-years), compared with 4451 reference individuals (0·38 per 1000 person-years; HR 1·59, 95% CI 1·46-1·72) during the same time period.”
> “The excess risks declined over calendar periods: during the last 5 years of follow-up (2013-17, Sweden only), the HR for incident CRC in people with UC was 1·38 (95% CI 1·20-1·60, or one additional case per 1058 patients with UC per 5 years) and the HR for death from CRC was 1·25 (95% CI 1·03-1·51, or one additional case per 3041 patients with UC per 5 years).”

Source: [Olén et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31929014/)

<a id="topic-2.2.1.7-4"></a>

### Extraintestinal manifestations: joint, ocular, or skin manifestations in 27% of patients

> “Fifty-two studies were included that reported on 352 454 patients. The prevalence of at least 1 joint, ocular, or skin extraintestinal manifestation in all IBD, UC, and CD was 24%, 27%, and 35% respectively.”

Source: [Kilic et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37042969/)

> “Overall risk of EIMs in patients with UC ranges from 7–17%, probably lower as compared to patients with CD, and approximately 1% patients may present with EIMs before UC diagnosis (13,16,64). Articular manifestations are the most frequently observed EIMs (8%), including peripheral arthritis (5.5%), and ankylosing spondylitis (1%), followed by cutaneous EIMs (1.3%), PSC (0.6%) and ocular manifestations (0.6%) (64,65).”
> “The cumulative incidence of spondyloarthropathy was 5%, 14%, and 22% at 10, 20 and 30y after UC diagnosis (66)”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.7-5"></a>

### Serious infections, venous thromboembolism, and cardiovascular events: contemporary US inception cohort

> “Cumulative 1- and 5y risk of serious infections in patients with UC was 5.3% (95% CI, 4.6–6.0) and 10.2% (95% CI, 9.1–11.4), respectively.”
> “Cumulative 1- and 5y risks of VTE were 0.1% (95% CI, 0.0–0.1) and 0.3% (95% CI, 0.1–0.5), and of MACE, was 0.2% (95% CI, 0.1–0.3) and 0.9% (95% CI, 0.5–1.3), respectively.”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.1.7-6"></a>

### Disability: work disability 1.8 times that of the general population

> “Patients with UC had 1.8 times higher risk of work disability (95% CI, 1.4–2.3) as compared to general population, and was comparable to that seen in patients with CD (56).”
> “While UC is not associated with an increased risk of mortality, it is associated with high morbidity and work disability.”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
